Hamilton CA, Cheung MK, Osann K, Chen L, Teng NN, Longacre TA, Powell MA, Hendrickson MR, Kapp DS, Chan JK (2006) Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. Br J Cancer 94:642–646

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tortorella L, Langstraat CL, Weaver AL, McGree ME, Bakkum-Gamez JN, Dowdy SC, Cliby WA, Keeney GL, Sherman ME, Weroha SJ, Mariani A, Podratz KC (2018) Uterine serous carcinoma: reassessing effectiveness of platinum-based adjuvant therapy. Gynecol Oncol 149:291–296

Article  CAS  PubMed  Google Scholar 

Menderes G, Clark M, Santin AD (2016) Novel targeted therapies in uterine serous carcinoma, an aggressive variant of endometrial cancer. Discov Med 21:293–303

PubMed  Google Scholar 

Rossi EC (2020) Identifying the worst of the worst: HER2 positive early stage uterine papillary serous carcinoma. Gynecol Oncol 159:1–2

Article  PubMed  Google Scholar 

Erickson BK, Najjar O, Damast S, Blakaj A, Tymon-Rosario J, Shahi M, Santin A, Klein M, Dolan M, Cimino-Mathews A, Buza N, Ferriss JS, Stone RL, Khalifa M, Fader AN (2020) Human epidermal growth factor 2 (HER2) in early stage uterine serous carcinoma: a multi-institutional cohort study. Gynecol Oncol 159:17–22

Article  CAS  PubMed  PubMed Central  Google Scholar 

Twomey JD, Brahme NN, Zhang B (2017) Drug-biomarker co-development in oncology - 20 years and counting. Drug Resist Updat 30:48–62

Article  PubMed  Google Scholar 

Xu M, Schwartz P, Rutherford T, Azodi M, Santin A, Silasi D, Martel M, Hui P (2010) HER-2/neu receptor gene status in endometrial carcinomas: a tissue microarray study. Histopathology 56:269–273

Article  PubMed  Google Scholar 

Fader AN, Roque DM, Siegel E, Buza N, Hui P, Abdelghany O, Chambers SK, Secord AA, Havrilesky L, O’Malley DM, Backes F, Nevadunsky N, Edraki B, Pikaart D, Lowery W, ElSahwi KS, Celano P, Bellone S, Azodi M, Litkouhi B, Ratner E, Silasi DA, Schwartz PE, Santin AD (2018) Randomized phase II trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-trastuzumab in uterine serous carcinomas that overexpress human epidermal growth factor receptor 2/Neu. J Clin Oncol 36:2044–2051

Article  CAS  PubMed  Google Scholar 

Fader AN, Roque DM, Siegel E, Buza N, Hui P, Abdelghany O, Chambers S, Secord AA, Havrilesky L, O’Malley DM, Backes FJ, Nevadunsky N, Edraki B, Pikaart D, Lowery W, ElSahwi K, Celano P, Bellone S, Azodi M, Litkouhi B, Ratner E, Silasi DA, Schwartz PE, Santin AD (2020) Randomized phase II trial of carboplatin-paclitaxel compared with carboplatin-paclitaxel-trastuzumab in advanced (stage III-IV) or recurrent uterine serous carcinomas that overexpress Her2/Neu (NCT01367002): updated overall survival analysis. Clin Cancer Res 26:3928–3935

Article  PubMed  PubMed Central  Google Scholar 

National Comprehensive Cancer Network. Uterine Neoplasms (Version 4.2019). https://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf. Accessed Oct 2019

Jenkins TM, Cantrell LA, Stoler MH, Mills AM (2022) HER2 overexpression and amplification in uterine carcinosarcomas with serous morphology. Am J Surg Pathol 46:435–442

Article  PubMed  Google Scholar 

Buza N (2021) HER2 testing and reporting in endometrial serous carcinoma: practical recommendations for HER2 immunohistochemistry and fluorescent in situ hybridization: proceedings of the ISGyP Companion Society Session at the 2020 USCAP Annual Meeting. Int J Gynecol Pathol 40:17–23

Article  PubMed  Google Scholar 

Buza N, Hui P (2013) Marked heterogeneity of HER2/NEU gene amplification in endometrial serous carcinoma. Genes Chromosomes Cancer 52:1178–1186

Article  CAS  PubMed  Google Scholar 

Buza N, English DP, Santin AD, Hui P (2013) Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice. Mod Pathol 26:1605–1612

Article  CAS  PubMed  Google Scholar 

Paver EC, Cooper WA, Colebatch AJ, Ferguson PM, Hill SK, Lum T, Shin JS, O’Toole S, Anderson L, Scolyer RA, Gupta R (2021) Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation. Pathology 53:141–156

Article  CAS  PubMed  Google Scholar 

Banet N, Shahi M, Batista D, Yonescu R, Tanner EJ, Fader AN, Cimino-Mathews A (2021) HER-2 amplification in uterine serous carcinoma and serous endometrial intraepithelial carcinoma. Am J Surg Pathol 45:708–715

Article  PubMed  Google Scholar 

Santin AD, Bellone S, Van Stedum S, Bushen W, Palmieri M, Siegel ER, De Las Casas LE, Roman JJ, Burnett A, Pecorelli S (2005) Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma. Cancer 104:1391–1397

Article  CAS  PubMed  Google Scholar 

Togami S, Sasajima Y, Oi T, Ishikawa M, Onda T, Ikeda S, Kato T, Tsuda H, Kasamatsu T (2012) Clinicopathological and prognostic impact of human epidermal growth factor receptor type 2 (HER2) and hormone receptor expression in uterine papillary serous carcinoma. Cancer Sci 103:926–932

Article  CAS  PubMed  PubMed Central  Google Scholar 

Morrison C, Zanagnolo V, Ramirez N, Cohn DE, Kelbick N, Copeland L, Maxwell GL, Fowler JM (2006) HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients. J Clin Oncol 24:2376–2385

Article  CAS  PubMed  Google Scholar 

Grushko TA, Filiaci VL, Mundt AJ, Ridderstråle K, Olopade OI, Fleming GF (2008) An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 108:3–9

Article  CAS  PubMed  Google Scholar 

Klc TR, Wu S, Wilhite AM, Jones NL, Powell MA, Olawaiye A, Girda E, Brown J, Puechl A, Ali-Fehmi R, Winer IS, Herzog TJ, Korn WM, Erickson BK (2022) HER2 in uterine serous carcinoma: testing platforms and implications for targeted therapy. Gynecol Oncol 167:289–294

Article  CAS  PubMed  Google Scholar 

Quddus MR, Hansen K, Tantravahi U, Sung CJ (2020) Human epidermal growth factor receptor 2 (Her2) testing for uterine serous carcinoma: report of scenarios of unusual overexpression. Gynecol Oncol Rep 32:100561

Article  PubMed  PubMed Central  Google Scholar 

Rottmann D, Assem H, Matsumoto N, Wong S, Hui P, Buza N (2021) Does specimen type have an impact on HER2 status in endometrial serous carcinoma? Discordant HER2 status of paired endometrial biopsy and hysterectomy specimens in the presence of frequent intratumoral heterogeneity. Int J Gynecol Pathol 40:263–271

Article  CAS  PubMed  Google Scholar 

Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, Bilous M, Ellis IO, Fitzgibbons P, Hanna W, Jenkins RB, Press MF, Spears PA, Vance GH, Viale G, McShane LM, Dowsett M (2018) Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline focused update. J Clin Oncol 36:2105–2122

Article  CAS  PubMed  Google Scholar 

Wakatsuki T, Yamamoto N, Sano T, Chin K, Kawachi H, Takahari D, Ogura M, Ichimura T, Nakayama I, Osumi H, Matsushima T, Suenaga M, Shinozaki E, Hiki N, Ishikawa Y, Yamaguchi K (2018) Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer. J Gastroenterol 53:1186–1195

Article  CAS  PubMed  PubMed Central  Google Scholar 

Muller KE, Marotti JD, Tafe LJ (2019) Pathologic features and clinical implications of breast cancer with HER2 intratumoral genetic heterogeneity. Am J Clin Pathol 152:7–16

Article  PubMed  Google Scholar 

Santin AD, Bellone S, Van Stedum S, Bushen W, De Las Casas LE, Korourian S, Tian E, Roman JJ, Burnett A, Pecorelli S (2005) Determination of HER2/neu status in uterine serous papillary carcinoma: comparative analysis of immunohistochemistry and fluorescence in situ hybridization. Gynecol Oncol 98:24–30

Article  CAS  PubMed  Google Scholar 

Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, Tsurutani J, Ueno NT, Prat A, Chae YS, Lee KS, Niikura N, Park YH, Xu B, Wang X, Gil-Gil M, Li W, Pierga JY, Im SA, Moore HCF, Rugo HS, Yerushalmi R, Zagouri F, Gombos A, Kim SB, Liu Q, Luo T, Saura C, Schmid P, Sun T, Gambhire D, Yung L, Wang Y, Singh J, Vitazka P, Meinhardt G, Harbeck N, Cameron DA, Investigators DE-BT (2022) Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med 387:9–20

Article  CAS  PubMed  PubMed Central  Google Scholar 

Black J, Menderes G, Bellone S, Schwab CL, Bonazzoli E, Ferrari F, Predolini F, De Haydu C, Cocco E, Buza N, Hui P, Wong S, Lopez S, Ratner E, Silasi DA, Azodi M, Litkouhi B, Schwartz P